Adam J Esbenshade
Children's Oncology Group · Vanderbilt-Ingram Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Adam J Esbenshade as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:39 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07848568 · Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of EpendymomaChildren's Oncology Group · not yet recruiting · Childhood Posterior Fossa Ependymoma · principal investigator
- N/ANCT00993694 · Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With DapsoneVanderbilt University · completed · Chronic Myeloproliferative Disorders, Leukemia, Lymphoma · principal investigator
- N/ANCT00801346 · Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in RemissionVanderbilt University Medical Center · completed · Fatigue, Leukemia, Long-term Effects Secondary to Cancer Therapy in Children · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- COG NCTN Network Group Operations CenterU10CA180886 · NCI · COG RESEARCH FOUNDATION, LLC · PI Douglas S. Hawkins · fiscal years 2015 to 2026Named on NCT07848568
- Leadership Planning and EvaluationP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · fiscal years 2015 to 2026Named on NCT00993694, NCT00801346
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:39 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- 77 citationsRCR 3.7
- 53 citationsRCR 10.1
- Obesity and insulin resistance in pediatric acute lymphoblastic leukemia worsens during maintenance therapy.Pediatr Blood Cancer · 201344 citationsRCR 1.5
- 35 citationsRCR 1.3
- 35 citationsRCR 7.3
- Prospective Evaluation of Galactomannan and (1→3) β-d-Glucan Assays as Diagnostic Tools for Invasive Fungal Disease in Children, Adolescents, and Young Adults With Acute Myeloid Leukemia Receiving Fungal Prophylaxis.J Pediatric Infect Dis Soc · 202127 citationsRCR 2.0
- A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant.J Pediatric Infect Dis Soc · 202125 citationsRCR 2.0
- 21 citationsRCR 1.6
- Incidence of acute kidney injury among pediatric hematology/oncology patients receiving vancomycin in combination with piperacillin/tazobactam or cefepime.Pediatr Blood Cancer · 201910 citationsRCR 0.6
- Working memory training in pediatric brain tumor survivors after recent diagnosis: Challenges and initial effects.Appl Neuropsychol Child · 202210 citationsRCR 1.0